General Information - malecare.org

A New Phase III Trial of ODM-201 for Men with Castrate Resistant Prostate Cancer without Visible Metastases

Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company) have announced that they have begun enrollment in a randomized Phase III clinical trial of a new investigational treatment for men with advanced prostate cancer. ODM-201 is a novel, oral androgen receptor inhibitor. The trial named ARAMIS trial is a randomized, Phase III, multi-center, double-blind, placebo-controlled [...]

By Malecare|2021-02-17T11:03:15-05:00September 21st, 2014|Advanced Prostate Cancer, Androgan Receptor Inhibitor, Drugs & Treatments, General Information, Hormone Therapy, OMD-201, Uncategorized|1 Comment

Chemo-Brain and ADT for Advanced Prostate Cancer – Does It Exist?

When I went on my first round of hormone therapy (ADT) I experienced severe cognitive side effects. I found it impossible to concentrate, read and remember anything. I lost the ability to navigate the New York City subways no less drive my car to a destination. Occasionally, when I was attempting to navigate the subway [...]

By Malecare|2017-10-19T10:48:02-04:00September 15th, 2014|ADT, Advanced Prostate Cancer, General Information, Hormone Therapy, Me, Quality of Life, Research, Uncategorized, Understanding APC|5 Comments

Sharing My Harry Pinchot Acceptance Speech

As I shared on this blog earlier thanks to many of you I was awarded the 2014 Harry Pinchot award. This prestigious award is made annually by the Prostate Cancer Research Institute (PCRI) and is given at their annual gala dinner which was this past Saturday night. I was joined at my table by my [...]

By Malecare|2017-10-19T10:48:02-04:00September 11th, 2014|Advanced Prostate Cancer, Advocacy, General Information, Uncategorized|1 Comment

Xtandi (enzaludamide) Receives FDA Approval in the Pre-Chemo Stage of Prostate Cancer Treatment

Expected and extraordinary news today on the new treatment front. Medivation and Astellas’ Xtandi (enzalutamide) was approved for use in men with castrate resistant prostate cancer. The new FDA approved label for Xtandi says that it is for the treatment of men with metastatic castration-resistant prostate cancer. This label is basically the same as for [...]

By Malecare|2014-09-10T17:03:53-04:00September 10th, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, enzalutamide, General Information, survival, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Thank You My Readers for Your Support in Being Awarded the Harry Pinchot Service Award

I recently was informed that I am to honored with the 2014 Harry Pinchot Award from the Prostate Cancer Research Institute. The award recognizes outstanding dedication and support to the prostate cancer community. I am pleased and flattered to be one of this year's receptients.I have been told that one reason I have received this [...]

By Malecare|2017-10-19T10:48:04-04:00August 26th, 2014|Advanced Prostate Cancer, General Information, Uncategorized|9 Comments